|
【结 构 式】 
|
【药物名称】SB-265123 【化学名称】2-[3-[3-(Pyridin-2-ylamino)propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10(R)-yl]acetic acid 【CA登记号】206113-21-5, 221900-22-7 ((S)-isomer), 210485-62-4 (undefined isomer) 【 分 子 式 】C25H26N2O3 【 分 子 量 】402.49757 |
【开发单位】GlaxoSmithKline (Originator) 【药理作用】Bone Diseases, Treatment of, Bone Resorption Inhibitors, METABOLIC DRUGS, Treatment of Osteoporosis, Integrin alphavbeta3 (Vitronectin) Antagonists, Integrin alphavbeta5 Antagonists |
合成路线1
Addition of phenylmagnesium bromide to 6-methoxy-1-indanone (I) gave carbinol (II), which was dehydrated to phenylindene (III) upon treatment with p-toluenesulfonic acid in refluxing toluene. Oxidative cleavage of (III) with Jones reagent in the presence of OsO4 provided 2-benzoyl-4-methoxyphenylacetic acid (IV), which was further reduced to the 2-benzyl analogue (V) by hydrogenation over Pd/C. After conversion of (V) to the corresponding acid chloride (VI) using oxalyl chloride and a trace of DMF, Friedel-Crafts cyclization with AlCl3 furnished the dibenzocycloheptenone (VII). Addition of the lithium enolate of ethyl acetate to the carbonyl group of (VII) in the presence of tetramethylethylenediamine at -78 C generated the hydroxyester (VIII). Then, hydrogenolysis of the benzylic alcohol of (VIII) in the presence of Pd/C gave (IX). Subsequent cleavage of the methyl ether of (IX) by means of ethane thiol and AlCl3 provided the corresponding racemic phenol. Isolation of the required (S)-enantiomer (X) was carried out by chiral HPLC.
| 【1】 Drake, F.H. (SmithKline Beecham plc); Method for stimulating bone formation. EP 0946180; WO 9815278 . |
| 【2】 Miller, W.H.; Samanen, J.M.; Heerding, D.; Bondinell, W.E. (SmithKline Beecham Corp.); Vitronectin receptor antagonists. EP 1025090; WO 9915508 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| 17491 | ethyl acetate | 141-78-6 | C4H8O2 | 详情 | 详情 | |
| 17616 | bromo(phenyl)magnesium; Phenyl Magnesium Bromide | 100-58-3 | C6H5BrMg | 详情 | 详情 | |
| (I) | 34514 | 6-methoxy-1-indanone | 13623-25-1 | C10H10O2 | 详情 | 详情 |
| (II) | 34515 | 6-methoxy-1-phenyl-1-indanol | C16H16O2 | 详情 | 详情 | |
| (III) | 34516 | 5-methoxy-3-phenyl-1H-indene; methyl 3-phenyl-1H-inden-5-yl ether | C16H14O | 详情 | 详情 | |
| (IV) | 34517 | 2-(2-benzoyl-4-methoxyphenyl)acetic acid | C16H14O4 | 详情 | 详情 | |
| (V) | 34518 | 2-(2-benzyl-4-methoxyphenyl)acetic acid | C16H16O3 | 详情 | 详情 | |
| (VI) | 34519 | 2-(2-benzyl-4-methoxyphenyl)acetyl chloride | C16H15ClO2 | 详情 | 详情 | |
| (VII) | 34520 | 3-methoxy-5,11-dihydro-10H-dibenzo[a,d]cyclohepten-10-one | C16H14O2 | 详情 | 详情 | |
| (VIII) | 34521 | ethyl 2-(10-hydroxy-3-methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl)acetate | C20H22O4 | 详情 | 详情 | |
| (IX) | 34522 | ethyl 2-(3-methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl)acetate | C20H22O3 | 详情 | 详情 | |
| (X) | 34523 | ethyl 2-[(10S)-3-hydroxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl]acetate | C19H20O3 | 详情 | 详情 |
合成路线2
Condensation of 2-chloropyridine-N-oxide hydrochloride (XI) with 3-amino-1-propanol (XII) in boiling tert-amyl alcohol provided the aminopyridine N-oxide (XIII). Subsequent Mitsunobu coupling of (XIII) with the chiral phenol (X) in the presence of diisopropyl azodicarboxylate and triphenyl phosphine produced ether (XIV). The N-oxide group of (XIV) was then reduced by transfer hydrogenation using cyclohexene and Pd/C to yield pyridine (XV). Finally, saponification of the ethyl ester of (XV) furnished the title compound.
| 【1】 Drake, F.H. (SmithKline Beecham plc); Method for stimulating bone formation. EP 0946180; WO 9815278 . |
| 【2】 Miller, W.H.; Samanen, J.M.; Heerding, D.; Bondinell, W.E. (SmithKline Beecham Corp.); Vitronectin receptor antagonists. EP 1025090; WO 9915508 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (X) | 34523 | ethyl 2-[(10S)-3-hydroxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl]acetate | C19H20O3 | 详情 | 详情 | |
| (XI) | 34524 | 2-chloro-1-pyridiniumolate | 2402-95-1 | C5H4ClNO | 详情 | 详情 |
| (XII) | 18522 | 3-amino-1-propanol | 156-87-6 | C3H9NO | 详情 | 详情 |
| (XIII) | 34525 | 2-[(3-hydroxypropyl)amino]-1-pyridiniumolate | C8H12N2O2 | 详情 | 详情 | |
| (XIV) | 34526 | 2-[(3-[[(10S)-10-(2-ethoxy-2-oxoethyl)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-3-yl]oxy]propyl)amino]-1-pyridiniumolate | C27H30N2O4 | 详情 | 详情 | |
| (XV) | 34527 | ethyl 2-[(10S)-3-[3-(2-pyridinylamino)propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl]acetate | C27H30N2O3 | 详情 | 详情 |
合成路线3
The synthesis of the tricyclic precursors has been reported by two alternative routes. Alkylation of 3-(3-methoxyphenyl)indene (XVI) with ethyl bromoacetate using lithium hexamethyldisilazide provided indeneacetate (XVII). Subsequent oxidative cleavage of (XVII) gave rise to the arylsuccinic derivative (XVIII). The benzoyl group of (XVIII) was then reduced to the benzyl analogue (XIX) by catalytic hydrogenation in the presence of Pd/C in AcOH. After conversion of (XIX) to the corresponding acid chloride (XX), Friedel-Crafts cyclization produced the tricyclic ketoester (XXI). Then reduction of the ketone group of (XXI) by hydrogenation over Pd/C furnished intermediate (IX).
| 【1】 Miller, W.H.; Samanen, J.M.; Heerding, D.; Bondinell, W.E. (SmithKline Beecham Corp.); Vitronectin receptor antagonists. EP 1025090; WO 9915508 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| 16640 | Ethyl 2-bromoacetate; Ethyl bromoacetate | 105-36-2 | C4H7BrO2 | 详情 | 详情 | |
| (IX) | 34522 | ethyl 2-(3-methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl)acetate | C20H22O3 | 详情 | 详情 | |
| (XVI) | 34528 | 3-(3-methoxyphenyl)-1H-indene; 3-(1H-inden-3-yl)phenyl methyl ether | C16H14O | 详情 | 详情 | |
| (XVII) | 34529 | ethyl 2-[3-(3-methoxyphenyl)-1H-inden-1-yl]acetate | C20H20O3 | 详情 | 详情 | |
| (XVIII) | 34530 | 4-ethoxy-2-[2-(3-methoxybenzoyl)phenyl]-4-oxobutyric acid | C20H20O6 | 详情 | 详情 | |
| (XIX) | 34531 | 4-ethoxy-2-[2-(3-methoxybenzyl)phenyl]-4-oxobutyric acid | C20H22O5 | 详情 | 详情 | |
| (XX) | 34532 | ethyl 4-chloro-3-[2-(3-methoxybenzyl)phenyl]-4-oxobutanoate | C20H21ClO4 | 详情 | 详情 | |
| (XXI) | 34533 | ethyl 2-(3-methoxy-11-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl)acetate | C20H20O4 | 详情 | 详情 |
合成路线4
In a further procedure, 2-benzyl-4-methoxyphenol (XXII) was converted to triflate (XXIII), and then allylated to give (XXIV) using allyl tributyl tin. Cleavage of the allylic olefin with ruthenium tetroxide produced carboxylic acid (V). Formation of the acid chloride (VI), followed by Friedel-Crafts cyclization as above afforded tricyclic ketone (VII).
| 【1】 Cousins, R.D.; Bondinell, W.E.; Miller, W.H.; et al.; Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett 1999, 9, 13, 1807. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (V) | 34518 | 2-(2-benzyl-4-methoxyphenyl)acetic acid | C16H16O3 | 详情 | 详情 | |
| (VI) | 34519 | 2-(2-benzyl-4-methoxyphenyl)acetyl chloride | C16H15ClO2 | 详情 | 详情 | |
| (VII) | 34520 | 3-methoxy-5,11-dihydro-10H-dibenzo[a,d]cyclohepten-10-one | C16H14O2 | 详情 | 详情 | |
| (XXII) | 34534 | 2-benzyl-4-methoxyphenol | C14H14O2 | 详情 | 详情 | |
| (XXIII) | 34535 | 2-benzyl-4-methoxyphenyl trifluoromethanesulfonate | C15H13F3O4S | 详情 | 详情 | |
| (XXIV) | 34536 | 4-allyl-3-benzylphenyl methyl ether; 1-allyl-2-benzyl-4-methoxybenzene | C17H18O | 详情 | 详情 |